Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04436029 |
Recruitment Status :
Recruiting
First Posted : June 17, 2020
Last Update Posted : June 17, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Myeloma Multiple | Biological: Descartes 11 | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 30 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy |
Actual Study Start Date : | June 12, 2020 |
Estimated Primary Completion Date : | April 2022 |
Estimated Study Completion Date : | April 2025 |

Arm | Intervention/treatment |
---|---|
Experimental: Descartes 11 |
Biological: Descartes 11
Car T-cells |
- Rate of stringent complete response [ Time Frame: 2 years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients must be 18 years of age or older at the time of enrollment
- High-risk multiple myeloma patients who complete pre-transplant induction treatment anti- myeloma drug combination (minimum 2 drugs).
Exclusion Criteria:
- Patients who are pregnant or lactating.
- Patients who have any active and uncontrolled infection. No blood cultures are necessary unless clinically indicated.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04436029
Contact: Adam S Chowdhury, MD | 3013488698 | adam.chowdhury@cartesiantx.com |
United States, Maryland | |
Center for Cancer and Blood Disorders | Recruiting |
Bethesda, Maryland, United States, 20817 | |
Contact: Investigator | |
Principal Investigator: Ralph Boccia, MD | |
United States, Wisconsin | |
Medical College of Wisconsin | Not yet recruiting |
Madison, Wisconsin, United States, 53226 | |
Contact: Investigator | |
Principal Investigator: Binod Dhakal, MD |
Responsible Party: | Cartesian Therapeutics |
ClinicalTrials.gov Identifier: | NCT04436029 |
Other Study ID Numbers: |
DC 11B |
First Posted: | June 17, 2020 Key Record Dates |
Last Update Posted: | June 17, 2020 |
Last Verified: | June 2020 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Multiple Myeloma Neoplasms, Plasma Cell Neoplasms by Histologic Type Neoplasms Hemostatic Disorders Vascular Diseases Cardiovascular Diseases |
Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Lymphoproliferative Disorders Immunoproliferative Disorders Immune System Diseases |